Molecular Characteristics, Oncogenic Roles, and Relevant Immune and Pharmacogenomic Features of EVA1B in Colorectal Cancer

Abstract

ObjectiveEVA1B, a protein coding gene, is a critical paralog of EVA1A gene. Herein, our study was conducted to investigate the role of EVA1B in colorectal cancer (CRC) progression and prognosis.MethodsPan-cancer analysis was conducted to analyze expression, genetic and epigenetic alterations, and immunological characteristics of EVA1B. Especially, immunological characteristics and mutational landscape were compared between high and low EVA1B expression groups in the combined TCGA-COAD and TCGA-READ datasets. Through random survival forest analysis, an EVA1B-derived genomic model was developed, and its prognostic value was verified in the external datasets (GSE14333, GSE39582, and GSE87211). Drug sensitivity was compared between high- and low-risk subpopulations. A nomogram was conducted through integrating independent factors.ResultsEVA1B expression presented a remarkable upregulation in most cancer types, especially CRC. EVA1B expression was significantly correlated to DNA methyltransferases, DNA mismatch repair genes, m6A regulators, TMB, and MSI across pan-cancer. High EVA1B expression indicated an undesirable CRC patients’ prognosis. Additionally, its upregulation was correlated to enhanced immune cell infiltration, increased stromal and immune activation, and elevated activities of cancer immunity cycle. Higher frequencies of amplification and deletion were investigated in high EVA1B expression subpopulation. Following verification, the EVA1B-derived genomic model reliably predicted patients’ prognosis and drug responses. The nomogram (age, stage, EVA1B-derived risk score) was conducted to quantify an individual’s survival probability. Furthermore, our experimental validation based on immunohistochemistry indicated that EVA1B overexpression is correlated with CRC tumorigenesis and poor outcomes in our CRC patients’ cohort.ConclusionCollectively, our findings provided valuable resource for guiding the mechanisms and therapeutic analysis of EVA1B in CRC.

Combination of theoretical analysis and experiments: Exploring the role of PLA2G7 in human cancers, including renal cancer

“…Surgical resection combined with chemotherapy is presently the preferred therapeutic strategy for most patients with advanced cancer [ 38 ]. Clinical trials are underway to explore immunotherapy as a supplementary curative and palliative treatment, potentially offering a novel strategy for patients with advanced or inoperable disease [ 39 , 40 ]. However, the development of precision and individualized tumor therapy is somewhat constrained by the lack of effective diagnostic and therapeutic targets.…”

Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer

“…In addition, in BC cells and tumor tissues, FBLN5 expression downregulates the activation of the NF-κB signaling pathway to promote BC cell proliferation and migration ( 32 ). Studies have shown that EVA1B expression is upregulated in colon cancer and glioma ( 33 , 34 ). However, few EVA1B-related studies have been found in BC.…”

Integrative analysis of TROAP with molecular features, carcinogenesis, and related immune and pharmacogenomic characteristics in soft tissue sarcoma

“…The correlation between the TROAP expression level and these processes was also confirmed. Finally, the immune checkpoints were extracted from previous studies to explore the relationship between TROAP and immune checkpoints 40–43 …”

“…TROAP‐relevant genes with p value < 0.05 were determined as prognostic factors, which were input into the out‐of‐bag data (OOB) algorithm to obtain essential variables with the minimum value of OOB. Finally, the gene set with the highest accuracy was confirmed by the SVMRFE machine algorithm, and a prognostic model was constructed using multivariate Cox regression analysis 40 . The TROAP‐relevant risk score was calculated according to the expression and regression coefficient of the model gene.…”